(Japanese)
(Japanese)
(Japanese)
Dramatically
Accelerating
Infectious Disease Research.
Our MPV* and Mylc** cells, produced with regenerative medicine technologies, will solve the shortage of experimental cells for researches on malaria and other infectious diseases, and help researchers accelerate their experiments exponentially.
* We are now providing test
and pilot products and will
start full-scale production in 2020.
** We start to sell this product from 12th Dec in 2019.
NEWS RELEASE
April 20 ,2020
We are attending COVID-19 Virtual Partnering event to find collaborators to develop solutions
April 14 ,2020
Our activities was introduced on the site of the discover the deep tech startups fighting COVID-19
March 27,2020
Announcing an ideal human blood cell, Mylc, for coronavirus COVID-19 research
PRODUCT Video
PRODUCT LINE-UP
Mpv
immature
red blood-like cells for
Malaria (P.vivax)
research
Mylc
special
myeloid lineage cells for
Dengue and other infectious diseases
